Replimune Group (NASDAQ:REPL) CAO Andrew Schwendenman Sells 7,632 Shares of Stock

Replimune Group, Inc. (NASDAQ:REPL) CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the sale, the chief accounting officer directly owned 99,425 shares of the company’s stock, valued at approximately $1,289,542.25. This represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Up 11.6%

Replimune Group stock opened at $15.24 on Thursday. The business’s 50-day simple moving average is $10.44 and its two-hundred day simple moving average is $7.69. The company has a debt-to-equity ratio of 0.63, a quick ratio of 4.79 and a current ratio of 4.79. The company has a market cap of $1.28 billion, a PE ratio of -4.51 and a beta of 0.88. Replimune Group, Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $15.68.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Equities analysts anticipate that Replimune Group, Inc. will post -2.7 EPS for the current year.

Institutional Investors Weigh In On Replimune Group

A number of large investors have recently made changes to their positions in REPL. International Assets Investment Management LLC acquired a new stake in shares of Replimune Group in the fourth quarter valued at approximately $29,000. CWM LLC boosted its stake in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the last quarter. Allworth Financial LP purchased a new stake in Replimune Group in the 2nd quarter valued at $62,000. Essential Partners LLC increased its stake in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its stake in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after acquiring an additional 1,879 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing strengthens liquidity: Replimune priced a $150 million underwritten offering, giving the clinical-stage biotechnology company additional capital to fund development of its oncology pipeline and lead candidate RP1. The financing appears to have eased concerns about near-term funding needs, although it may dilute existing shareholders. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Analysts raised ratings and price targets: Wedbush, Leerink Partners and JPMorgan recently became more bullish on REPL. JPMorgan lifted its target to $20, while Leerink raised its target to $17 and upgraded the shares to outperform. Cantor Fitzgerald also maintained an overweight rating. This improving analyst stance suggests greater confidence in Replimune’s prospects, though the reported consensus target of $11.86 is below the current trading range. Replimune Shares Rise After Pricing of Offering
• Neutral Sentiment: Executives sold shares for tax obligations: CEO Sushil Patel, CFO Emily Hill, CAO Andrew Schwendenman and insider Konstantinos Xynos collectively sold approximately 69,868 shares worth about $906,000 at an average price of $12.97. The SEC filings state that the sales covered tax withholding related to vested equity awards, and each executive retained a substantial position. As a result, the transactions offer limited evidence of weakening confidence, but could still draw investor attention after the stock’s recent advance. SEC insider transaction filing
• Negative Sentiment: Multiple law firms publicized a securities class action: Lawsuits filed on behalf of investors who purchased REPL securities between October 20, 2025, and April 10, 2026, allege that Replimune misled investors about RP1’s efficacy, commercial viability and unresolved FDA study-design concerns. CEO Sushil Patel and CFO Emily Hill are named as individual defendants, and October 5, 2026 is the lead-plaintiff deadline. The allegations have not been proven, but the litigation adds legal, financial and reputational uncertainty. Replimune securities class action notice

Analyst Ratings Changes

Several analysts have recently commented on the stock. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price for the company in a research report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Replimune Group in a report on Wednesday. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group has an average rating of “Moderate Buy” and an average target price of $11.86.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.